Amphastar P - Asset Resilience Ratio
Amphastar P (AMPH) has an Asset Resilience Ratio of 7.48% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check AMPH strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Amphastar P's Asset Resilience Ratio has changed over time. See Amphastar P balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Amphastar P's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Amphastar P market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $123.21 Million | 7.48% |
| Total Liquid Assets | $123.21 Million | 7.48% |
Asset Resilience Insights
- Limited Liquidity: Amphastar P maintains only 7.48% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Amphastar P Industry Peers by Asset Resilience Ratio
Compare Amphastar P's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Amphastar P (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Amphastar P.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.91% | $112.64 Million | $1.63 Billion | +2.47pp |
| 2024-12-31 | 4.44% | $70.04 Million | $1.58 Billion | -3.00pp |
| 2023-12-31 | 7.44% | $112.51 Million | $1.51 Billion | +4.79pp |
| 2022-12-31 | 2.65% | $19.66 Million | $741.99 Million | +1.11pp |
| 2021-12-31 | 1.54% | $10.32 Million | $671.53 Million | -0.52pp |
| 2020-12-31 | 2.06% | $12.98 Million | $631.24 Million | -0.32pp |
| 2019-12-31 | 2.38% | $13.96 Million | $586.97 Million | +1.83pp |
| 2018-12-31 | 0.55% | $2.83 Million | $513.56 Million | -0.03pp |
| 2017-12-31 | 0.58% | $2.63 Million | $454.67 Million | +0.46pp |
| 2016-12-31 | 0.12% | $527.00K | $427.74 Million | -0.21pp |
| 2015-12-31 | 0.33% | $1.28 Million | $390.14 Million | -0.05pp |
| 2014-12-31 | 0.38% | $1.50 Million | $389.37 Million | -0.01pp |
| 2013-12-31 | 0.39% | $1.32 Million | $338.75 Million | -0.20pp |
| 2012-12-31 | 0.59% | $1.89 Million | $317.48 Million | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more